| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hai-Ning Yuan, Chuan-Yue Wang, Cho Wing Sze, Yao Tong, Qing-Rong Tan, Xiu-Jie Feng, Rui-Mei Liu, Ji-Zhi Zhang, Yan-Bo Zhang, Zhang-Jin Zhan. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Journal of clinical psychopharmacology. vol 28. issue 3. 2008-09-11. PMID:18480682. |
this study was designed to compare the herbal preparation called peony-glycyrrhiza decoction (pgd) with bromocriptine (bmt), a dopamine agonist widely used for prl-secreting disorders, in the treatment of risperidone-induced hyperprolactinemia. |
2008-09-11 |
2023-08-12 |
human |
| Shen-Chieh Chang, Chun-Hsin Chen, Mong-Liang L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. General hospital psychiatry. vol 30. issue 4. 2008-09-10. PMID:18585544. |
cabergoline, a dopamine agonist, has been introduced on the market to treat hyperprolactinemia, even secondary to antipsychotic use. |
2008-09-10 |
2023-08-12 |
Not clear |
| L Vilar, M C Freitas, L A Naves, L A Casulari, M Azevedo, R Montenegro, A I Barros, M Faria, G C Nascimento, J G Lima, L H Nóbrega, T P Cruz, A Mota, A Ramos, A Violante, A Lamounier Filho, M R Gadelha, M A Czepielewski, A Glezer, M D Bronstei. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. Journal of endocrinological investigation. vol 31. issue 5. 2008-09-02. PMID:18560262. |
the aim of the study was to evaluate clinical and laboratorial features of 1234 patients with different etiologies of hyperprolactinemia, as well as the response of 388 patients with prolactinomas to dopamine agonists. |
2008-09-02 |
2023-08-12 |
Not clear |
| Munya A Al-Fulaij, Yong Ren, Martin Beinborn, Alan S Kopi. Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants. Journal of molecular neuroscience : MN. vol 34. issue 3. 2008-06-20. PMID:18210231. |
drugs targeting dopamine receptors have been the focus of much research over the past 30 years, in large part because of their role in treating multiple pathological conditions including parkinson's disease, schizophrenia, tourette's syndrome, and hyperprolactinemia. |
2008-06-20 |
2023-08-12 |
human |
| G Z Ziiazetdinova, A Ia Sapronova, V Ia Kiiasova, A K Nanaev, V S Kudrin, N Martina, I Tyllet, M V Ugriumo. [Compensatory reaction during degeneration of arcuate nucleus dopaminergic neurons in rats]. Zhurnal evoliutsionnoi biokhimii i fiziologii. vol 44. issue 1. 2008-06-03. PMID:18411516. |
the study has been carried out to verify the authors' hypothesis that degeneration of dopaminergic (da-ergic) neurons of the hypothalamic tuberoinfundibular system and concomitant development of hyperprolactinemia are accompanied by involvement of compensatory synthesis of dopamine (da) by non-dopaminergic neurons expressing single complementary enzymes of synthesis of this neurotransmitter. |
2008-06-03 |
2023-08-12 |
rat |
| Greg M Anderson, David C Kieser, Frederick J Steyn, David R Gratta. Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol. Endocrinology. vol 149. issue 4. 2008-05-06. PMID:18162529. |
chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction lh pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol. |
2008-05-06 |
2023-08-12 |
rat |
| Tatiana Mancini, Felipe F Casanueva, Andrea Giustin. Hyperprolactinemia and prolactinomas. Endocrinology and metabolism clinics of North America. vol 37. issue 1. 2008-04-01. PMID:18226731. |
any process interfering with dopamine synthesis, its transport to the pituitary gland, or its action at the level of lactotroph dopamine receptors can cause hyperprolactinemia. |
2008-04-01 |
2023-08-12 |
Not clear |
| Carolina Cristina, Graciela Díaz-Torga, Adrián Góngora, Maria Clara Guida, Maria Inés Perez-Millán, Alberto Baldi, Damasia Becu-Villalobo. Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice. American journal of physiology. Endocrinology and metabolism. vol 293. issue 5. 2007-12-18. PMID:17848635. |
dopamine d2 receptor (d2r) knockout (ko) female mice develop chronic hyperprolactinemia and pituitary hyperplasia. |
2007-12-18 |
2023-08-12 |
mouse |
| Ken H Darzy, Stephen M Shale. Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary. vol 8. issue 3-4. 2007-10-25. PMID:16508716. |
hyperprolactinemia, due to hypothalamic damage leading to reduced dopamine release, has been described in both sexes and all ages but is mostly seen in young women after intensive irradiation and is usually subclinical. |
2007-10-25 |
2023-08-12 |
Not clear |
| P Chanson, F Borson-Chazot, O Chabre, B Estou. Drug treatment of hyperprolactinemia. Annales d'endocrinologie. vol 68. issue 2-3. 2007-10-12. PMID:17532288. |
medical treatment of hyperprolactinemia is based upon use of dopamine agonists (da): bromocriptine, lisuride, quinagolide and cabergoline. |
2007-10-12 |
2023-08-12 |
Not clear |
| Joo-Cheol Shim, Jae-Goo K Shin, Deanna L Kelly, Do-Un Jung, Young-Soo Seo, Kwang-Hyeon Liu, Ji-Hong Shon, Robert R Conle. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728426. |
adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. |
2007-10-09 |
2023-08-12 |
Not clear |
| Yan-Nian Jiang, Yi-Hung Li, Meng-Wei Ke, Ting-Yu Tseng, Yueh-Bih Tang, Mu-Chiou Huang, Winston Teng-Kuei Cheng, Yu-Ten J. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis. Cancer cell international. vol 7. 2007-08-13. PMID:17331262. |
the dopamine d2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of tumor cell apoptosis, respectively, but the molecular mechanism of bromocriptine induction of pituitary tumor apoptosis remains unclear. |
2007-08-13 |
2023-08-12 |
human |
| Michał Karasek, Marek Pawlikowski, Andrzej Lewińsk. [Hyperprolactinemia: causes, diagnosis, and treatment]. Endokrynologia Polska. vol 57. issue 6. 2007-06-19. PMID:17253440. |
in patients in whom hyperprolactinemia has been confirmed the treatment with dopamine agonists (with prevalence of cabergoline, followed by quinagoline) is currently considered first-choice therapy. |
2007-06-19 |
2023-08-12 |
Not clear |
| P Murali Doraiswamy, Gisela Schott, Kristina Star, Ralph Edwards, Bruno Mueller-Oerlinghause. Atypical antipsychotics and pituitary neoplasms in the WHO database. Psychopharmacology bulletin. vol 40. issue 1. 2007-05-02. PMID:17285098. |
amisulpride and risperidone are potent dopamine d2 receptor blocking atypical antipsychotics that can cause hyperprolactinemia. |
2007-05-02 |
2023-08-12 |
mouse |
| Vincent Goffin, Philippe Touraine, Michael D Culler, Paul A Kell. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nature clinical practice. Endocrinology & metabolism. vol 2. issue 10. 2006-11-14. PMID:17024156. |
currently, therapeutic management of hyperprolactinemia relies on dopamine agonists, since dopamine is the primary physiological suppressor of pituitary prolactin production. |
2006-11-14 |
2023-08-12 |
Not clear |
| Greg M Anderson, Paulien Beijer, Angela S Bang, Mark A Fenwick, Stephen J Bunn, David R Gratta. Suppression of prolactin-induced signal transducer and activator of transcription 5b signaling and induction of suppressors of cytokine signaling messenger ribonucleic acid in the hypothalamic arcuate nucleus of the rat during late pregnancy and lactation. Endocrinology. vol 147. issue 10. 2006-10-24. PMID:16857756. |
during late pregnancy and lactation, the tuberoinfundibular dopamine (tida) neurons that regulate prolactin secretion by negative feedback become less able to produce dopamine in response to prolactin, leading to hyperprolactinemia. |
2006-10-24 |
2023-08-12 |
rat |
| Greg M Anderson, Paulien Beijer, Angela S Bang, Mark A Fenwick, Stephen J Bunn, David R Gratta. Suppression of prolactin-induced signal transducer and activator of transcription 5b signaling and induction of suppressors of cytokine signaling messenger ribonucleic acid in the hypothalamic arcuate nucleus of the rat during late pregnancy and lactation. Endocrinology. vol 147. issue 10. 2006-10-24. PMID:16857756. |
the loss of this stimulating pathway may underlie the reduced tuberoinfundibular dopamine neuron dopamine output and hyperprolactinemia that characterizes late pregnancy and lactation. |
2006-10-24 |
2023-08-12 |
rat |
| Carol Huang, Shereen Ezzat, Sylvia L Asa, Jill Hamilto. Dopaminergic resistant prolactinomas in the peripubertal population. Journal of pediatric endocrinology & metabolism : JPEM. vol 19. issue 7. 2006-10-17. PMID:16995577. |
we report two children with macroadenomas and hyperprolactinemia resistant to medical therapy using dopamine agonists, who experienced secondary pituitary dysfunction. |
2006-10-17 |
2023-08-12 |
Not clear |
| Bun-Hee Lee, Yong-Ku Ki. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 4. 2006-09-25. PMID:16466670. |
hyperprolactinemia can be induced by dopamine d2 receptor-binding drugs such as antipsychotic drugs. |
2006-09-25 |
2023-08-12 |
human |
| Medard M Lec. [The diagnosis of hyperprolactinemia in clinical practice]. Ginekologia polska. vol 76. issue 12. 2006-07-17. PMID:16566383. |
in the identification of hyperprolactinemia not only simple measurements of the prolactin serum level are used, the dynamic tests with the use of dopamine antagonists have a special role as well. |
2006-07-17 |
2023-08-12 |
Not clear |